New Breakthrough Drug Reduces Heart Attack Risk by 94%!
Revolutionary Treatment for Genetic Heart Conditions
American scientists have developed a groundbreaking drug, lepodisiran, that can nearly eliminate the risk of heart attacks caused by genetic factors. This new medication, administered as an annual vaccine, is said to keep heart diseases at bay. Researchers have confirmed that final safety trials are underway, and so far, no significant side effects have been reported.
Impact on Genetic Heart Diseases
The drug has been found to reduce the risk of hereditary heart disease by an impressive 94%, while also significantly lowering the chances of stroke. Lepodisiran is being manufactured by the renowned multinational pharmaceutical company Eli Lilly, which has announced plans to introduce it to the market soon. The drug’s efficacy was recently discussed at a conference at The University of Chicago, and details of the study have been published in the New England Journal of Medicine.
How lepodisiran Works
Medical experts have found that elevated levels of Lipoprotein(a) [Lp(a)] in the blood increase the likelihood of heart attacks. This protein, discovered in 1974, is genetically inherited and contributes to early-onset heart disease, sometimes even in individuals under 25 years of age. Scientists have confirmed that lepodisiran effectively regulates Lp(a) levels, thereby preventing heart attacks and strokes. When administered as a vaccine, this drug suppresses the production of excess Lipoprotein(a), significantly reducing cardiovascular risks.